Please login to the form below

Not currently logged in

Pfizer/BioNTech receives expanded authorisation from the FDA for its COVID-19 booster

The booster dose of the companies’ COVID-19 vaccine is now authorised to include individuals aged 12 years and older


The US Food and Drug Administration (FDA) has granted Pfizer-BioNTech an expanded emergency use authorisation (EUA) for the companies’ COVID-19 booster vaccine to include those aged 12 years and older in the United States.

With the FDA announcement, the time between the completion of the primary series and booster doses is significantly reduced for all eligible individuals. Moreover, the authorisation includes individuals aged between five and 11 who are immunocompromised in certain ways.

As with Pfizer/BioNTech’s initial vaccine, the booster dose will have the same dosage strength of 30-µg.

For those aged 5 years and older, the timeline given for the vaccine to be administered as part of a two-dose series is a total of three weeks between each jab.

In the same age group, 28 days must be allowed before a third dose can be given to those who are immunocompromised in certain ways.

The FDA authorisation is based on information provided by an independent evaluation, assessing the safety and effectiveness of a third dose in adults who have had solid organ transplants.

Previously, FDA authorisation was provided for a booster dose of the Pfizer/BioNTech COVID-19 vaccine for individuals aged 16 and older, while those eligible in the 18-and-older age groups also come under the authorisation, even if they have completed their primary vaccination with a different authorised COVID-19 vaccine.

Chairman and CEO of Pfizer, Albert Bourla said: “The recent rise in COVID-19 cases is concerning to all and today’s decision by the FDA to further expand the Emergency Use Authorization of a booster dose of our vaccine is critical to help us ultimately defeat this pandemic.”

Bourla added that Pfizer “continue to believe that broad use of boosters is essential to preserving a high level of protection against this disease and reducing the rate of hospitalisations”.

In 2021, Pfizer/BioNTech successfully fulfilled their target of delivering one billion COVID-19 vaccine doses to low and middle-income countries, with an expected projection to deliver an additional one billion doses to the same countries in 2022.

CEO and co-founder of BioNTech, Ugur Sahin, commented: “The booster vaccination increases the level of immunity and improves protection against COVID-19 across all age groups that have been authorised to receive one.”

Sahin added: “In the current situation, it is important to offer all eligible individuals a booster, particularly against the backdrop of the newly-emerging variants such as Omicron.”

Article by
Fleur Jeffries

4th January 2022

From: Research



COVID-19 Updates and Daily News

Featured jobs


Add my company
Envision Pharma Group

We are a global leader in the medical affairs space. Our purpose-built software and scientific solutions make us a unique...

Latest intelligence

When is an agency not an agency?
The PR Week UK Top 150 Consultancies prompts anticipation and curiosity. But can a virtual collective of freelancers fairly be compared and ranked against conventional agencies?...
Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...